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RepoRt
The Dombrock (Do) glycoprotein is a glycosylphosphatidylinositol 
(GPI)-linked membrane protein carrying Dombrock blood group 
antigens. There are no standardized typing reagents for Doa or 
Dob. We have developed ten different monoclonal antibodies 
(MoAbs) that are specific for Dombrock. The objectives of 
this study were to characterize these MoAbs serologically and 
determine the epitopes they recognize. MoAbs were generated by 
standard fusion methods. Mice were immunized with transfected 
human embryonic kidney 293T cells expressing high levels of 
Doa or Dob. The MoAbs were tested serologically with untreated 
and enzymatically or chemically modified red blood cells (RBCs). 
Serologic inhibition studies were performed with synthetic 
peptides corresponding to Doa and Dob amino acid sequences. 
Pepscan epitope analysis was done on an array of immobilized 
tridecapeptides corresponding to the full-length polypeptide. All 
ten antibodies were serologically specific for Dombrock. Eight of 
the antibodies recognized epitopes that were resistant to treatment 
with ficin, pronase, α-chymotrypsin, and neuraminidase, 
but sensitive to trypsin and 0.2 M dithiothreitol (DTT). Five 
have anti-Dob-like specificity. The epitope recognized by 
MIMA-52 was neuraminidase sensitive, and MIMA-127 epitope 
recognized a DTT-resistant, linear epitope 90QKNYFRMWQK99 
of the Dombrock polypeptide. MIMA-127 was the only one of 
the ten Dombrock MoAbs mapped to a specific sequence of the 
Dombrock glycoprotein; the other nine MoAbs did not provide a 
specific peptide binding pattern. The other MoAbs could not be 
mapped as they most likely recognize nonlinear, conformation-
dependent epitopes, as is evident by their sensitivity to reduction 
of disulfide bonds by DTT. The dependence of some epitopes on 
antigen glycosylation is also a possibility. Immunohematology 
2012;28:124–9.
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The Dombrock (Do) blood group glycoprotein (CD297) 
is an interesting glycosylphosphatidylinositol (GPI)-linked 
component of human erythrocyte membranes, identified as 
a polymorphic member of the adenosine diphosphate (ADP)-
ribosyltransferase gene family.1,2 The Dombrock glycoprotein 
carries the polymorphic Doa and Dob antigens and other 
high-prevalence antigens: Gregory (Gya), Holley (Hy), Joseph 
(Joa), DOYA, DOMR, and DOLG.3–7 Rare human antibodies 
to the Dombrock antigens, although only weakly reactive in 
vitro, have caused acute and delayed hemolytic transfusion 
reactions.8–10 The poor reactivity of the antibodies and the 
lack of fully characterized antisera and commercial red blood 
cells (RBCs) have created problems for resolving serologically 
difficult patient samples. Considering the importance of using 
well-defined antibodies in the studies on the Dombrock 
glycoprotein, we have produced several novel murine 
monoclonal antibodies (MoAbs) by immunizing mice with 
human embryonic kidney (HEK) cells that were transiently 
transfected to express the Dombrock antigens Doa or Dob. 
These antibodies were evaluated for their serologic specificity 
and were subjected to Pepscan epitope mapping and to peptide 
inhibition studies.
Materials and Methods
Transfection and Expression of Dombrock in HEK 
293T Cells
The full-length cDNA coding for the Doa and Dob transcripts 
was cloned in pIRES2-EGFP (pDI2E) vector (Clontech, 
Mountain View, CA), allowing the simultaneous expression of 
green fluorescent protein (GFP) and the Dombrock gene.2 HEK 
293T cells were transiently transfected with 10 μg of Doa and 
Dob cDNA expression constructs by the calcium phosphate 
transfection method and analyzed for surface expression using 
anti-Gya by flow cytometry as described previously.11 Briefly, 106 
transfected HEK 293T cells were incubated for 30 minutes at 
37°C with anti-Gya and, after several washes, were stained with 
phycoerythrin (PE)-conjugated horse anti-mouse IgG (H+L) 
(Vector Laboratories, Burlingame, CA), washed, and analyzed 
by flow cytometry (Canto, Becton Dickinson, San Jose, CA). On 
average, Dombrock expression was detected by flow cytometry 
on approximately 50 percent of transfected cells, consistent with 
a transfection efficiency of 50 percent (data not shown).
Hybridoma Production
HEK cells transiently transfected with Dombrock cDNA 
corresponding to Doa or Dob were used to immunize BALB/c 
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mice three times during a 6-week period by intravenous (IV) 
injection of 2 × 106 tHEK cells plus a murine CpG adjuvant.12 
Once adequate immunization was achieved, as demonstrated 
by hemagglutination of antigen-positive human RBCs, 
polyethylene glycol (PEG; Sigma Chemical Company, St. 
Louis, MO) fusions were done between the mouse splenocytes 
and X63-Ag8.653 mouse myeloma fusion partner cells. 
Briefly, the mouse splenocytes were mixed with the fusion 
partner X63.Ag8.653 cells at a ratio of roughly 3:1 and washed 
with phosphate-buffered saline (PBS) without calcium (Ca2+) 
or magnesium (Mg2+) (GIBCO/Invitrogen, Grand Island, 
NY). Fusions were achieved by the addition of 1 mL of PEG 
(with 5% DMSO; Sigma) dropwise slowly for 60 seconds with 
constant mixing followed by constant mixing at 37°C for 
90 seconds. Then 1 mL of PBS (without Ca2+ and Mg2+) was 
added in a dropwise fashion for 60 seconds, repeated once, 
and then 1 mL of PBS was added for 30 seconds, repeated 
once, and then topped off to a volume of 15 mL with PBS. 
The cells were then allowed to rest at 37°C, followed by 
gentle centrifugation at 1000 rpm for 5 minutes and washed 
in warmed HAMS/DF-12 culture medium (Sigma) with 10 
percent fetal bovine serum added (Hyclone Laboratories, Inc., 
Logan, UT). The cells were then plated onto sterile 96-well 
tissue culture trays (BD Falcon, Franklin Lakes, NJ) at 1.5 
million cells per well in HAMS/DF-12 with hypoxanthine, 
aminopterin, and thymidine added (HAT; Sigma). After 7 
days, 100 μL of additional culture medium with supplemental 
growth factors (StemCell Technologies, Vancouver, BC) was 
added to each well.
Screening Fusion Trays for Antibody Secretion
The plates were analyzed 14 days after fusion for the 
presence of antibodies by hemagglutination as follows: a 50-
μL aliquot of supernatant fluid from each well was added to 
the corresponding wells of a 96-well v-bottom assay tray 
(Greiner Bio-One, Longwood, FL), 25 μL of a 1 percent RBC 
suspension of screening cells was added, and the trays were 
mixed on a titer plate shaker (Lab-Line Instruments, Melrose 
Park, IL). After 30 minutes the trays were observed for direct 
agglutination. The wells were washed by adding 100 μL PBS, 
mixing, and centrifuging at 1000 rpm for 30 seconds. The 
wash PBS was flicked off by inverting the tray over the sink and 
blotting dry on a paper towel. For indirect agglutination, 50 μL 
of anti-mouse IgG (The Binding Site, San Diego, CA) that had 
been diluted 1:100 in 6 percent albumin in PBS was added to 
each well, mixed, and incubated for 30 minutes, then observed 
for agglutination. The desired hybrids were then cloned three 
times by limiting dilution to assure monoclonality.
Serologic Evaluation and Synthetic Peptide Inhibition 
Studies
The final culture of each hybrid was grown in vitro, and the 
supernatant fluid was tested for reactivity by standard tube and 
gel hemagglutination methods using normal and chemically or 
enzymatically treated RBCs. Enzyme treatments with papain, 
trypsin, α-chymotrypsin, pronase, and neuraminidase and 
chemical treatment with 0.2 M DTT were done using standard 
methods described elsewhere.13 Hemagglutination inhibitions 
were performed in two stages: first incubating equal volumes 
(50 µL) of antibody with the synthetic peptide at a concentration 
of 1 µg/µL, mixing and incubating 30 minutes. Next, one drop 
of 3 percent RBCs suspended in PBS was added to each tube 
and hemagglutination was performed as described earlier to 
complete each test.
Epitope Mapping Using Immobilized Peptides
Eighty-one tridecapeptides (peptides consisting of 13 
amino acids) synthesized on pins, which covered the sequence 
corresponding to the full-length membrane-bound Dombrock 
protein (i.e., amino acid residues 45–297, which lacks the 
leader sequence and phosphatidylinositol glycan-anchoring 
sequences), were obtained from Mimotopes (Clayton, Victoria, 
Australia). The selected decapeptides were synthesized 
using the epitope scanning kit purchased from Mimotopes. 
The decapeptides were synthesized on activated plastic 
pins fixed to the plate corresponding to a 96-well microtiter 
plate. The syntheses were done by stepwise elongation of the 
peptides from C- to N-terminus, following the manufacturer’s 
instructions.
Binding of the antibodies to tridecapeptides and 
decapeptides on pins was tested as described.14–17 The pins 
were consecutively immersed (with washing between the 
incubations) in the wells containing (1) the test MoAbs, 
incubated overnight at 4°C, (2) alkaline phosphatase–
conjugated goat anti-mouse IgG (Dako, Copenhagen, 
Denmark), incubated for 1 hour at ambient room temperature, 
and (3) phosphatase substrate tablets (Sigma). The absorbance 
of the substrate solution samples was read at 405 nm in a 
microtiter plate reader (PerkinElmer 2300 multiplate reader, 
Melrose Park, IL). The test antibodies were used at dilutions of 
1:20, if not stated otherwise.
Results
Serologic Characterization of the Antibodies
The MoAbs from ten hybridomas were Dombrock-
specific as they reacted with all Dombrock-positive RBCs 
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but not with Gy(a–) and Hy– RBCs. Five were anti-Dob-like 
by hemagglutination as they reacted, after selected dilution 
in 6 percent albumin in PBS, with Do(a–b+) or Do(a+b+) 
RBCs, but not with several examples of Do(a+b–) RBCs. 
The remaining five recognized epitopes independent of the 
Doa/Dob polymorphism. The MoAbs, all isotype IgG2a, had 
similar reactivity patterns with enzymatically treated or 
chemically modified RBCs, with a few exceptions (Table 1). 
The epitopes recognized by all or most MoAbs were resistant 
to ficin or pronase, α-chymotrypsin, and neuraminidase 
treatment and were sensitive to trypsin and 0.2 M DTT 
treatment. The most important exceptions were MIMA-52, 
which was unique in that it was specific for a neuraminidase-
sensitive epitope, and MIMA-127, which recognized an 
epitope sensitive to α-chymotrypsin and resistant to DTT 
treatment.
Pepscan Epitope Mapping
The results of hemagglutination of protease-treated RBCs 
did not reveal any information about the epitopes that each 
MoAb recognized on the Dombrock molecule because it is not 
known which peptide bonds of the Dombrock polypeptide 
chain are hydrolyzed by the proteases used. For initial epitope 
mapping a panel of 81 tridecapeptides, covering the entire 
membrane-bound sequence of the Dombrock glycoprotein, 
was used (Fig. 1). Each tridecapeptide differed by three 
Table 1. Serologic reactivity of Dombrock monoclonal antibodies
Monoclonal antibody Clone ID Specificity Ficin Papain Trypsin Chymotrypsin Neuraminidase DTT
MIMA-52 10B5 Do protein NT R S R S W
MIMA-53 8E9 Do protein NT R S R R S
MIMA-55 7H6/F7 Dob NT R S R R S
MIMA-64 7H6/B3 Dob NT R S W R S
MIMA-73 15D6 Dob NT R S R R S
MIMA-98 7D10 Do protein R NT S W R S
MIMA-123 6B5 Dob R NT S R R S
MIMA-125 5A11 Do protein NT R S R R S
MIMA-127 7C8 Do protein R NT S S NT R
MIMA-143 1G8 Dob NT R S R R S
ID= identification; DTT = dithiothreitol; NT = not tested; R = resistant; S = sensitive; W = weaker reactivity after treatment.
Bold font highlights the significant differences in MoAb reactivity.
Fig. 1 Amino acid sequence of the Dombrock glycoprotein. The blood group Doa/Dob polymorphism at amino acid residue 265 is shown. 
Five potential N-glycosylation sites are underlined. Epitope for the MIMA-127 antibody is highlighted in gray.
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amino acids sequentially from the next and corresponded to 
amino acid residues 45–297 of the Dombrock glycoprotein 
(UniProt entry Q93070, Fig. 1). Of these ten MoAbs, only one 
antibody, MIMA-127, displayed a specific and strong binding 
to the peptides 87–100 (IEAQKNYFRMWQK) and 90–103 
(QKNYFRMWQKAHL; Fig. 2A). To verify this observation, a 
set of nine decapeptides (shown in Fig. 2B), corresponding to 
the sequence of amino acids 86DIEAQKNYFRMWQKAHLA103 
of Dombrock, was synthesized on pins. MIMA-127 bound 
most strongly to the decapeptide 90–99 and more weakly to 
the peptide 91–100 (Fig. 2B). The binding to the decapeptides 
was weaker than to the respective tridecapeptides (at 20-
fold antibody dilution) and was increased when the more 
concentrated dilution of the antibody was used. Thus, our 
results confirmed that MIMA-127 recognizes the sequence 
90QKNYFRMWQK99, present in all of the most active peptides. 
The stronger reactivity of the antibody with the tridecapeptides 
than with decapeptides suggests that amino acid residues 
flanking this epitope may play a role in antibody binding 
owing to conformational changes in the protein. Testing other 
antibodies at fivefold dilution did not increase their binding to 
any peptides.
The Doa and Dob blood group antigens differ by the 
presence of asparagine (Asn) and aspartic acid (Asp), 
respectively, at position 265 of the Dombrock glycoprotein. 
Our set of tridecapeptides contained Asn at this position, 
which contributed to a lack of binding of antibodies identified 
serologically as anti-Dob-like. To test these antibodies, two sets 
of six decapeptides, covering the amino acid sequence 258–
272 of Dob and differing by the presence of Asn265 or Asp265, 
were used. However, no Dob-like antibodies bound to these 
peptides (data not shown).
Inhibition of Antibodies With Soluble Peptides
Synthetic peptides corresponding to the amino acid 
sequence surrounding the Doa/Dob polymorphism at position 
265 were used in inhibition assays. We used Dob-specific 
peptides that were either 15 (261HPRGDWLQLRSTGNL275), 
Fig. 2 Mapping the MIMA-127. Pins made with the peptides listed were incubated with MIMA-127 followed by mouse IgG, then alkaline 
phosphatase, and the absorbance was measured at 405 nm. Binding to the tridecapeptides (A) and decapeptides (B) is shown. Dilution of 
the antibody solution used in the experiments is indicated. The sequence of the most active tridecapeptides and a decapeptide is shown and 
their common sequence fragment (epitope) is boxed.
A B
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16 (255VINMSYHPRGDWLQLR270), or 21 (255VINMSYHPRG 
DWLQLRSTGNL275) amino acids in length. None of the 
Dombrock MoAbs were inhibited by these synthetic peptides.
Discussion
We have produced ten different murine hybridoma cell 
lines that secreted monoclonal antibodies specific to the 
Dombrock glycoprotein, and five of them were anti-Dob-like by 
serologic testing. An attempt to identify the epitopes detected 
by the MoAbs on the Dombrock glycoprotein was successful 
only for MIMA-127. Our results showed that MIMA-127 
recognizes a relatively long linear epitope formed by amino 
acid residues 90–99 of the Dombrock glycoprotein (Fig. 
2). The results indicated that peptide 89–98, which did not 
contain Lys99, and peptide 91–100 without Gln90, were less 
active than peptide 90–99. Lack of specific reactivity of other 
antibodies with synthetic peptides suggests that the MoAbs 
recognize conformation-dependent nonlinear epitopes. The 
Dombrock glycoprotein contains five cysteine residues that 
can form two disulfide bonds, resulting in the formation of 
nonlinear epitopes.2 This conclusion is strongly supported by 
our finding that all epitopes recognized by the MoAbs were 
destroyed by treatment of RBCs with DTT (reduction of 
disulfide bonds), except the epitope for MIMA-127, which was 
DTT-resistant.
On the other hand, the lack of reactivity of anti-Dob-like 
MoAbs with immobilized and soluble peptides covering the 
blood group polymorphism region may be attributable to the 
absence of glycosylation on the synthetic peptides. There are 
two potential N-glycosylation sites, at Asn257 and Asn274 
residues flanking the Doa/Dob (Asn265Asp) polymorphism 
site. The effect of glycosylation on peptidic epitope reactivity 
can differ: an antibody can recognize both amino acids and 
carbohydrates (glycopeptidic epitope), or an oligosaccharide 
chain may interact with amino acid residues in a manner 
that changes the local conformation of the polypeptide chain 
and may result in exposing or burying the adjacent peptidic 
epitope.18 One of these possibilities can also apply to the 
reactivity of MIMA-52, which recognized a sialic acid–
dependent epitope.
A lack of interaction of other antibodies either with 
immobilized or with soluble synthetic linear peptides and 
sensitivity of the epitopes to DTT suggests that most Dombrock 
monoclonal antibodies recognize nonlinear, conformation-
dependent epitopes. For some of the antibodies the effect of 
antigen glycosylation on the reactivity of epitopes cannot be 
ruled out. However, all antibodies obtained were shown to 
be specific for the Dombrock protein and can be used for its 
identification on the erythrocyte surface.
Despite several attempts using similar methods of 
immunization with transfected cells, we were not successful 
in producing a monoclonal antibody with Doa-like specificity. 
It may be worth attempting immunization with synthetic 
peptides that are specific for Doa; however, conformation 
and glycosylation appear to play important roles in antigen 
recognition to stimulate the immune system for antibodies 
with Doa specificity.
Antibodies to Dombrock blood group antigens are typically 
weakly reactive, and thus they are often misidentified. The 
monoclonal antibodies reported in this manuscript are typical 
in that they are not strongly reactive, and their use in serologic 
testing must be carefully controlled. Testing in gel cards with 
anti-mouse IgG has proved to be the best method for antigen 
typing to identify antigen-negative donor units and to be 
helpful in resolving serologically difficult patient samples by 
phenotyping their RBCs.19 Though the mouse IgG gel cards 
are currently not available in the United States, we developed 
a method of converting neutral gel cards into mouse IgG gel 
cards for this purpose. 
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